B-Cell Lymphomas

Common Name(s)

B-Cell Lymphomas

Lymphoma is the most common blood cancer. Lymphocytes are a type of white blood cell that are part of our body’s immune system and help our body fight infections. Lymphoma occurs when these lymphocytes grow and multiply uncontrollably. The body has two main types of lymphocytes, B-lymphocytes (B-cells) and T-lymphocytes (T-cells). B-cell lymphoma occurs when the B-cells in particular grow into lymphomas. The cancerous lymphocyte cells can then travel to various parts of the body including the lymph nodes, blood, spleen, bone marrow and other organs. There are many different types of B-cell lymphomas and the most common type is called diffuse large b-cell lymphoma (DLBCL) which is aggressive (fast-growing) and requires immediate treatment. There are other forms that are slow-growing and respond well to treatment and can go into remission for many years. Genetic factors as well as environmental factors, weak immune system (immunodeficiency due to an organ transplant or HIV/AIDS), drug and chemical exposures, viruses and other unknown factors are thought to play a role in the development of lymphoma.

Symptoms are variable but can include: swollen lymph glands, fevers, night sweats, fatigue, unexplained weight loss, pain or abdominal bloating, chest pain, cough, difficulty breathing. Diagnosis may include physical exam of the lymph nodes, spleen and liver, blood tests, x-rays, scans, and finally a biopsy from lymph tissue. The treatment and prognosis or outlook depends upon the specific type of B-cell lymphoma and other factors present but often includes radiation, chemotherapy and medications. Speak with your physician for the most current treatment options. Support groups are also a great resource for support and information and can help connect you to other individuals with B-cell lymphoma.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "B-Cell Lymphomas" returned 581 free, full-text research articles on human participants. First 3 results:

Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas.
 

Author(s): Laura Broutier, Marion Creveaux, Jonathan Vial, Antonin Tortereau, Jean-Guy Delcros, Guillaume Chazot, Mark J McCarron, Sophie Léon, Céline Pangault, Nicolas Gadot, Amélie Colombe, Marie-Laure Boulland, Jonathan Blachier, Julien C Marie, Alexandra Traverse-Glehen, Olivier Donzé, Catherine Chassagne-Clément, Gilles Salles, Karin Tarte, Patrick Mehlen, Marie Castets

Journal:

 

DCC (Deleted in Colorectal Carcinoma) has been demonstrated to constrain tumor progression by inducing apoptosis unless engaged by its ligand netrin-1. This has been shown in breast and colorectal cancers; however, this tumor suppressive function in other cancers is not established. ...

Last Updated: 17 Feb 2016

Go To URL
Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.
 

Author(s): Rui Wu, Marcel Nijland, Bea Rutgers, Rianne Veenstra, Myra Langendonk, Lotte E van der Meeren, Philip M Kluin, Guanwu Li, Arjan Diepstra, Jen-Fu Chiu, Anke van den Berg, Lydia Visser

Journal:

 

Follicular lymphoma and diffuse large B cell lymphomas comprise the main entities of adult B cell malignancies. Although multiple disease driving gene aberrations have been identified by gene expression and genomic studies, only a few studies focused at the protein level. We applied ...

Last Updated: 12 Jan 2016

Go To URL
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
 

Author(s): Mélanie Juilland, Montserrat Gonzalez, Tabea Erdmann, Yara Banz, Zala Jevnikar, Stephan Hailfinger, Alexandar Tzankov, Michael Grau, Georg Lenz, Urban Novak, Margot Thome

Journal: Blood. 2016 Apr;127(14):1780-9.

 

A hallmark of the diffuse large B-cell lymphoma (DLBCL) of the activated B-cell (ABC) type, a molecular subtype characterized by adverse outcome, is constitutive activation of the transcription factor nuclear factor-κB (NF-κB), which controls expression of genes promoting cellular ...

Last Updated: 8 Apr 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "B-Cell Lymphomas" returned 42 free, full-text review articles on human participants. First 3 results:

Cutaneous primary B-cell lymphomas: from diagnosis to treatment.
 

Author(s): Margarida Lima

Journal: An Bras Dermatol. ;90(5):687-706.

 

Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells neoplasms with tropism for the skin, whose biology and clinical course differ significantly from the equivalent nodal lymphomas. The most indolent forms comprise the primary cutaneous marginal zone and ...

Last Updated: 12 Nov 2015

Go To URL
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.
 

Author(s): M A Lunning, M R Green

Journal:

 

Subtypes of non-Hodgkin's lymphomas align with different stages of B-cell development. Germinal center B-cell (GCB)-like diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Burkitt's lymphoma (BL) each share molecular similarities with normal GCB cells. Recent next-generation ...

Last Updated: 17 Oct 2015

Go To URL
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.
 

Author(s): Steven H Swerdlow, Isinsu Kuzu, Ahmet Dogan, Stephan Dirnhofer, John K C Chan, Birgitta Sander, German Ott, Luc Xerri, Leticia Quintanilla-Martinez, Elias Campo

Journal: Virchows Arch.. 2016 Mar;468(3):259-75.

 

Plasmacytic differentiation may occur in almost all small B cell lymphomas (SBLs), although it varies from being uniformly present (as in lymphoplasmacytic lymphoma (LPL)) to very uncommon (as in mantle cell lymphomas (MCLs)). The discovery of MYD88 L265P mutations in the vast majority ...

Last Updated: 29 Mar 2016

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
 

Status: Recruiting

Condition Summary: B-cell Lymphoma

 

Last Updated: 14 Mar 2016

Go to URL

Last Updated: 23 Aug 2016

Go to URL
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
 

Status: Recruiting

Condition Summary: B-Cell Lymphoma

 

Last Updated: 22 Nov 2016

Go to URL